- Correction
- Open access
- Published:
Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
BMC Psychiatry volume 22, Article number: 170 (2022)
The Original Article was published on 11 December 2021
Correction to: BMC Psychiatry 21, 622 (2021)
http://orcid.org/10.1186/s12888-021-03608-1
Following publication of the original article [1], the authors identified errors in the text. Below is a table of corrections which have been implemented in the original article.
Section | Originally published text | Corrected text |
Abstract | Treatment response and remission rates were 65 and 40%, respectively. | Treatment response and remission rates were approximately 65 and 40%, respectively. |
Results - Baseline characteristics | Overall, study participants were predominantly white (69.2%), female (82.8%), and≤55years of age (77.9%). Mean PHQ-9 score was 15.7 (moderately severe depression), and 59.5% of the patients were employed. | Overall, study participants were predominantly white (69.2%), female (82.8%), and ≤55 years of age (77.9%). Mean PHQ-9 score was 15.7 (moderately severe depression), and 58.3% of the patients were employed. |
Results - Safety and tolerability | Overall, 117 AEs were reported by 59 patients. | Overall, 117 AEs deemed related to study treatment were reported by 59 patients. |
Availability of Data and Materials | The Goal Attainment Scale adapted for depression (Global Attainment Scale – Depression © 2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved) | The Goal Attainment Scale adapted for depression (Goal Attainment Scale – Depression © 2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved) |
The original article [1] has been corrected.
Reference
McCue M, et al. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. BMC Psychiatry. 2021;21:622. https://doi.org/10.1186/s12888-021-03608-1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
McCue, M., Sarkey, S., Eramo, A. et al. Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. BMC Psychiatry 22, 170 (2022). https://doi.org/10.1186/s12888-022-03798-2
Published:
DOI: https://doi.org/10.1186/s12888-022-03798-2